Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review

The coronavirus disease of 2019 (COVID-19) has caused significant morbidity and mortality among infected individuals across the world. High transmissibility rate of the causative virus – Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – has led to immense strain and bottlenecking of the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kritika Srinivasan, Mana Rao
Formato:	article
Lenguaje:	EN
Publicado:	SAGE Publishing 2021
Materias:	Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/85abae68d6764e3ea80fae177c22c749
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:85abae68d6764e3ea80fae177c22c749
record_format	dspace
spelling	oai:doaj.org-article:85abae68d6764e3ea80fae177c22c7492021-12-05T03:03:22ZUnderstanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review2049-937X10.1177/20499361211063016https://doaj.org/article/85abae68d6764e3ea80fae177c22c7492021-12-01T00:00:00Zhttps://doi.org/10.1177/20499361211063016https://doaj.org/toc/2049-937XThe coronavirus disease of 2019 (COVID-19) has caused significant morbidity and mortality among infected individuals across the world. High transmissibility rate of the causative virus – Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – has led to immense strain and bottlenecking of the health care system. While noteworthy advances in vaccine development have been made amid the current global pandemic, most therapeutic agents are repurposed from use in other viral infections and are being evaluated for efficacy in COVID-19. Favipiravir, an orally administered drug originally developed in Japan against emerging influenza viral strains, has been shown to have widespread application and safety across multiple ribonucleic acid (RNA) viral infections. With a strong affinity toward the viral RNA-dependent RNA polymerase (RdRp), favipiravir could be a promising therapy against SARS-CoV-2, by targeting downstream viral RNA replication. Initial trials for usage in COVID-19 have suggested that favipiravir administration during initial infection stages, in individuals with mild to moderate infection, has a strong potential to improve clinical outcomes. However, additional well-designed clinical trials are required to closely examine ideal timing of drug administration, dosage, and duration, to assess the role of favipiravir in COVID-19 therapy. This review provides evidence-based insights and throws light on the current clinical trials examining the efficacy of favipiravir in tackling COVID-19, including its mechanism, pharmacodynamics, and pharmacokinetics.Kritika SrinivasanMana RaoSAGE PublishingarticleInfectious and parasitic diseasesRC109-216ENTherapeutic Advances in Infectious Disease, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Infectious and parasitic diseases RC109-216
spellingShingle	Infectious and parasitic diseases RC109-216 Kritika Srinivasan Mana Rao Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
description	The coronavirus disease of 2019 (COVID-19) has caused significant morbidity and mortality among infected individuals across the world. High transmissibility rate of the causative virus – Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – has led to immense strain and bottlenecking of the health care system. While noteworthy advances in vaccine development have been made amid the current global pandemic, most therapeutic agents are repurposed from use in other viral infections and are being evaluated for efficacy in COVID-19. Favipiravir, an orally administered drug originally developed in Japan against emerging influenza viral strains, has been shown to have widespread application and safety across multiple ribonucleic acid (RNA) viral infections. With a strong affinity toward the viral RNA-dependent RNA polymerase (RdRp), favipiravir could be a promising therapy against SARS-CoV-2, by targeting downstream viral RNA replication. Initial trials for usage in COVID-19 have suggested that favipiravir administration during initial infection stages, in individuals with mild to moderate infection, has a strong potential to improve clinical outcomes. However, additional well-designed clinical trials are required to closely examine ideal timing of drug administration, dosage, and duration, to assess the role of favipiravir in COVID-19 therapy. This review provides evidence-based insights and throws light on the current clinical trials examining the efficacy of favipiravir in tackling COVID-19, including its mechanism, pharmacodynamics, and pharmacokinetics.
format	article
author	Kritika Srinivasan Mana Rao
author_facet	Kritika Srinivasan Mana Rao
author_sort	Kritika Srinivasan
title	Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
title_short	Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
title_full	Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
title_fullStr	Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
title_full_unstemmed	Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
title_sort	understanding the clinical utility of favipiravir (t-705) in coronavirus disease of 2019: a review
publisher	SAGE Publishing
publishDate	2021
url	https://doaj.org/article/85abae68d6764e3ea80fae177c22c749
work_keys_str_mv	AT kritikasrinivasan understandingtheclinicalutilityoffavipiravirt705incoronavirusdiseaseof2019areview AT manarao understandingtheclinicalutilityoffavipiravirt705incoronavirusdiseaseof2019areview
_version_	1718372625644781568

Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review

Ejemplares similares